|
1
|
Dannenberg AJ and Subbaramaiah K:
Targeting cyclooxygenase-2 in human neoplasia: rationale and
promise. Cancer Cell. 4:431–436. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hasegawa K, Ohashi Y, Ishikawa K, et al:
Expression of cyclooxygenase-2 in uterine endometrial cancer and
anti-tumor effects of a selective COX-2 inhibitor. Int J Oncol.
26:1419–1428. 2005.PubMed/NCBI
|
|
3
|
Genç S, Attar E, Gürdöl F, Kendigelen S,
Bilir A and Serdaroğlu H: The effect of COX-2 inhibitor,
nimesulide, on angiogenetic factors in primary endometrial
carcinoma cell culture. Clin Exp Med. 7:6–10. 2007.PubMed/NCBI
|
|
4
|
Wood NJ, Quinton NA, Burdall S, Sheridan E
and Duffy SR: Exploring the potential chemopreventative effect of
aspirin and rofecoxib on hereditary nonpolyposis colorectal
cancer-like endometrial cancer cells in vitro through mechanisms
involving apoptosis, the cell cycle, and mismatch repair gene
expression. Int J Gynecol Cancer. 17:447–454. 2007. View Article : Google Scholar
|
|
5
|
Sooriakumaran P, Coley HM, Fox SB,
Macanas-Pirard P, Lovell DP, Henderson A, et al: A randomized
controlled trial investigating the effects of celecoxib in patients
with localized prostate cancer. Anticancer Res. 29:1483–1488.
2009.PubMed/NCBI
|
|
6
|
Hasegawa K, Torii Y, Ishii R, Oe S, Kato R
and Udagawa Y: Effects of a selective COX-2 inhibitor in patients
with uterine endometrial cancers. Arch Gynecol Obstet.
284:1515–1521. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Soriano AF, Helfrich B, Chan DC, et al:
Synergistic effects of new chemopreventive agents and conventional
cytotoxic agents against human lung cancer cell lines. Cancer Res.
59:6178–6184. 1999.PubMed/NCBI
|
|
8
|
Hida T, Kozaki K, Ito H, et al:
Significant growth inhibition of human lung cancer cells both in
vitro and in vivo by the combined use of a selective cyclooxygenase
2 inhibitor, JTE-522, and conventional anticancer agents. Clin
Cancer Res. 8:2443–2447. 2002.PubMed/NCBI
|
|
9
|
Altorki NK, Keresztes JL, Port JL, Libby
DM, Korst RJ, Flieder DB, et al: Celecoxib, a selective
cyclo-oxygenase-2 inhibitor, enhances the response to preoperative
paclitaxel and carboplatin in early-stage non-small-cell lung
cancer. J Clin Oncol. 21:2645–2650. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lipton A, Campbell-Baird C, Witters L,
Harvey H and Ali S: Phase II trial of gemcitabine, irinotecan, and
celecoxib in patients with advanced pancreatic cancer. J Clin
Gastroenterol. 44:286–288. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aruajo AM, Mendez JC, Coelho AL, Sousa B,
Barata F, Figueiredo A, et al: Phase II study of celecoxib with
cisplatin plus etoposide in extensive-stage small cell lung cancer.
Cancer Invest. 27:391–396. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ratnasinghe D, Daschner PJ, Anver MR, et
al: Cyclooxygenase-2, P-glycoprotein-170 and drug resistance: Is
chemoprevention against multidrug resistance possible? Anticancer
Res. 21:2141–2147. 2001.PubMed/NCBI
|
|
13
|
Patel VA, Dunn MJ and Sorokin A:
Regulation of MDR-1 (p-glycoprotein) by cyclooxygenase-2. J Biol
Chem. 277:38915–38920. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sorokin A: Cyclooxygenase-2: potential
role in regulation of drug efflux and multidrug resistance
phenotype. Curr Pharm Des. 10:647–657. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zatelli MC, Luchin A, Piccin D, et al:
Cyclooxgenase-2 inhibitors reverse chemoresistance phenotype in
medullary thyroid carcinoma by a permeability glycoprotein-mediated
mechanism. J Clin Endocrinol Metab. 90:5754–5760. 2005. View Article : Google Scholar
|
|
16
|
Zatelli MC, Luchin A, Tagliati F, et al:
Cyclooxygenase-2 inhibitors prevent the development of
chemoresistance phenotype in a breast cancer cell line by
inhibiting glycoprotein p-170 expression. Endocr Relat Cancer.
14:1029–1038. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fontaine M, Elmquist WF and Miller DW: Use
of rhodamine 123 to examine the functional activity of
P-glycoprotein in primary cultured brain microvessel endothelial
cell monolayers. Life Sci. 59:1521–1531. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hille S, Rein DT, Riffelmann M, et al:
Anticancer drugs induce mdr1 gene expression in recurrent ovarian
cancer. Anticancer Drugs. 17:1041–1044. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zrieki A, Farinotti R and Buyse M:
Cyclooxygenase inhibitors down regulate P-glycoprotein in human
colorectal Caco-2 cell line. Pharm Res. 25:1991–2001. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fantappiè O, Masini E, Sardi I, et al: The
MDR phenotype is associated with the expression of COX-2 and iNOS
in a human hepatocellular carcinoma cell line. Hepatology.
35:843–852. 2002.
|
|
21
|
Raspollini MR, Amunni G, Villanucci A,
Boddi V and Taddei GL: Increased cyclooxygenase-2 (COX-2) and
P-glycoprotein-170 (MDR1) expression is associated with
chemotherapy resistance and poor prognosis. Analysis in ovarian
carcinoma patients with low and high survival. Int J Gynecol
Cancer. 15:255–260. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Surowiak P, Materna V, Denkert C, et al:
Significance of cyclooxygenase 2 and MDR1/P-glycoprotein
coexpression in ovarian cancers. Cancer Lett. 235:272–280. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xi H, Baldus SE, Warnecke-Eberz U, et al:
High cyclooxygenase-2 expression following neoadjuvant
radiochemotherapy is associated with minor histopathologic response
and poor prognosis in esophageal cancer. Clin Cancer Res.
11:8341–8347. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Saikawa Y, Sugiura T, Toriumi F, et al:
Cyclooxygenase-2 gene induction causes CDDP resistance in colon
cancer cell line, HCT-15. Anticancer Res. 24:2723–2728.
2004.PubMed/NCBI
|
|
25
|
Yamada T, Ueda M, Maeda T, et al:
Establishment and characterization of CA125 producing cell line
(OMC-2) originating from a human endometrial adenocarcinoma. Asia
Oceania J Obstet Gynecol. 15:403–416. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Puhlmann U, Ziemann C, Ruedell G, et al:
Impact of the cyclooxygenase system on doxorubicin-induced
functional multidrug resistance 1 overexpression and doxorubicin
sensitivity in acute myeloid leukemic HL-60 cells. J Pharmacol Exp
Ther. 312:346–354. 2005. View Article : Google Scholar
|
|
27
|
Chen C, Shen HL, Yang J, Chen QY and Xu
WL: Preventing chemoresistance of human breast cancer cell line,
MCF-7 with celecoxib. J Cancer Res Clin Oncol. 137:9–17. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bentires-Alj M, Barbu V, Fillet M, et al:
NF-κB transcription factor induces drug resistance through MDR1
expression in cancer cells. Oncogene. 22:90–97. 2003.
|
|
29
|
Daschner PJ, Ciolino HP, Plouzek CA and
Yeh GC: Increased AP-1 activity in drug resistant human breast
cancer MCF-7 cells. Breast Cancer Res Treat. 53:229–240. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
van Wijngaarden J, van Beek E, van Rossum
G, et al: Celecoxib enhances doxorubicin-induced cytotoxicity in
MDA-MB231 cells by NF-κB-mediated increase of intracellular
doxorubicin accumulation. Eur J Cancer. 43:433–442. 2007.PubMed/NCBI
|
|
31
|
Bassiouny AR, Zaky A and Neenaa HM:
Synergistic effect of celecoxib on 5-fluorouracil-induced apoptosis
in hepatocellular carcinoma patients. Ann Hepatol. 9:410–418.
2010.PubMed/NCBI
|
|
32
|
Sui H, Zhou S, Wang Y, et al: COX-2
contributes to P-glycoprotein-mediated multidrug resistance via
phosphorylation of c-Jun at Ser63/73 in colorectal cancer.
Carcinogenesis. 32:667–675. 2011. View Article : Google Scholar : PubMed/NCBI
|
